“…[ 264 ] Similarly, the issue of protracting the half‐life of oligonucleotide RNAs which are broadly used in non‐coding RNAs (ncRNAs)‐based therapies is of paramount importance. [ 265 ] Therefore, RNA silencing techniques are of great interest for suppressing the overexpression of genes encoding for tumor‐related proteins, receptors, and enzymes. [ 266 ] For this to happen, current strategies for delivering miRNA‐based therapies use novel delivery vehicles such as liposomes, micelles, polymersomes, dendrimers, nanotubes, artificial DNA nanostructures, and polymeric, silica, and metal NPs.…”